Radioligand Therapy Improves PFS and Responses in SSTR+ Grade 2/3 GEP-NETs
The use of lutetium 177Lu dotatate (Lutathera) and high-dose long-acting octreotide as frontline treatment for patients with newly diagnosed somatostatin receptor (SSTR)-positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) led to significant improvements in progression-free survival (PFS) compared with high-dose long-acting octreotide alone. "This would represent a new indication for first-line treatment of GEP-NETS. In addition, this would represent the first theranostic agent FDA approved for use in the 1st line setting," said Kunz, associate professor of Internal Medicine (Medical Oncology); director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; chief, GI Medical Oncology; vice chief, Diversity, Equity, and Inclusion, Medical Oncology.Source: Targeted Oncology
$20M Federal Grant Renewed for Yale Tobacco Center of Regulatory Science
The National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) have renewed a $20 million grant for the Yale Tobacco Center of Regulatory Science (TCORS). The Yale center is led by co-directors Suchitra Krishnan-Sarin, PhD, Albert E. Kent Professor of Psychiatry; and Stephanie O’Malley, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry.
Yale Researchers Make Progress in Advanced Lung Cancer Immunotherapy Recognition and Treatment
A recent Yale study found that a newly developed drug could show promise in slowing the progression of non-small cell lung cancer in patients for whom previous treatments had not been effective. Presented at the World Conference on Lung Cancer in Singapore in September, the study found that an immunotherapy medication called NC318 could increase the effectiveness of existing cancer treatments and provide an alternative treatment for patients who did not respond to prior immunotherapy. “In the end, we saw 28% of our patients who had, what we felt, was benefit from this therapy,” said Scott Gettinger, Chief of Thoracic Oncology at the Yale Cancer Center and the study’s lead author. “Which is promising, considering we don’t have anything else. If what we see early on pans out, then this offers a potential salvage therapy for patients who progressed after chemotherapy and immunotherapy, which is the majority of our patients.”Source: Yale Daily News
Stigma, Even Harm Common When Transgender People Meet With Doctors
Transgender people have a tough time receiving adequate medical care due to issues like voyeurism, being treated as abnormal and even being denied care due to their gender identity, a new study finds. “After clinicians learn that patients are trans, usually transgender people feel that their care gets worse and not better,” said study author Dr. Ash Alpert (pronouns: they/them). “A number of people in the study talked about how people started misgendering them after they learned that they were transgender instead of getting their pronouns right.” These medical experiences left the study participants stuck between choosing to reveal their gender identity and face transphobia or withholding their gender identity and consequently receiving ineffective medical care. They also discussed the fact that improving the safety of transgender people in the medical system is complicated due to the medical field being “inherently violent or stigmatizing of transgender people.”Source: USNews
They survived childhood cancer. But the disease has taken a toll on their mental health.
Nearly 16,000 children are diagnosed with cancer in the U.S. each year, according to the American Childhood Cancer Organization. Thanks to advances in treatment, survival rates in general are higher, but for survivors, there can be a hidden cost: their mental health.Source: Yahoo Life
PFAS and Phenols Linked to Different Cancers in Women of Different Races
A new federally-funded study in the Journal of Exposure Science & Environmental Epidemiology has found that compounds called phenols, and the synthetic chemicals PFAS, were linked to different kinds of cancer in white women and women of color. PFAS were linked to ovarian and uterine cancers mainly in white women, and phenols were linked more to breast cancer in non-white women. Phenols and PFAS are found in hundreds of daily consumer products. The researchers stated that the racial differences are particularly impactful because of racial disparities in exposure to these chemicals. Nicole Deziel, member of the Yale Cancer Center and associate professor of epidemiology (environmental sciences) at Yale School of Public Health, who is not associated with the study, said the findings “provided a lot of new information suggesting that exposure to PFAS could be associated with a variety of hormonally related cancers, particularly in women.”Source: CT Public Radio
Pathology Office of Research Affairs Makes an Impact
Gina Della Porta, left, Director of the Office of Research Affairs, and David Stern, Professor of Pathology and Vice Chair for Basic and Translational Sciences, who oversees the office. In just one year, the Department of Pathology’s Office of Research Affairs has made an impact.
Adopting New Diet and Exercise Routines may Improve Breast Cancer Remission
Researchers at the Yale Cancer Center have found that diet and fitness interventions in early-stage breast cancer patients may improve their outcomes. Melinda Irwin, deputy director of the Yale Cancer Center and a senior author of the study, has dedicated her life to cancer prevention research. While investigating various types of cancer, Irwin has observed the challenges that patients face in adhering to chemotherapy — a common cancer treatment that has many adverse side effects, including hair loss, weight gain and fatigue. These side effects can be so severe that some patients stop seeking treatment. “Physicians hear from women all the time that they wish they had better guidance and tools to help them through chemotherapy, especially to ward off side effects like fatigue, neuropathy and changes in body weight,” Irwin said.Source: Yale Daily News
Compression of Cancer Cells a Double-Edged Sword
Adhering closely to Darwin’s theory of evolution, tumors need to adapt to environmental changes to survive. A new study shows that one of those changes - the compression of cells - can both help and hinder the progression of cancer. The study, which looks specifically at melanoma cells, is published in the Proceedings of the National Academy of Sciences (PNAS) and was conducted in the lab of Michael Mak, assistant professor of biomedical engineering. Xingjian Zhang, a former Ph.D. student in Mak’s lab, is first author of the study.Source: Yale School of Engineering and Applied Science
Effect of Diet and Exercise Intervention on Chemotherapy Dose Intensity, Response Rate Among Patients With Breast Cancer
In the LEANer study, reported in the Journal of Clinical Oncology by Tara Sanft, MD, and colleagues, researchers found that an exercise and nutrition intervention did not improve relative dose intensity (RDI) among patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer, but did improve pathologic complete response rate among those receiving neoadjuvant chemotherapy.Source: The ASCO Post